The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (Q57703684)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)	article

Statements

scholarly article

0 references

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (English)

0 references

1 reference

based on heuristic

inferred from title

Giuseppe Remuzzi

10

object named as

G Remuzzi

0 references

author name string

B M Brenner

1

0 references

M E Cooper

2

0 references

D de Zeeuw

3

0 references

J P Grunfeld

4

0 references

W F Keane

5

0 references

K Kurokawa

6

0 references

J B McGill

7

0 references

W E Mitch

8

0 references

H H Parving

9

0 references

A B Ribeiro

11

0 references

M D Schluchter

12

0 references

D Snavely

13

0 references

Z Zhang

14

0 references

R Simpson

15

0 references

D Ramjit

16

0 references

S Shahinfar

17

0 references

language of work or name

0 references

publication date

December 2000

0 references

Journal of the Renin-Angiotensin-Aldosterone System

0 references

1

0 references

4

0 references

328-35

0 references

Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota.

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

NIDDM is the Major Cause of Diabetic End-Stage Renal Disease: More Evidence From a Tri-Ethnic Community

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

A simple method of estimating progression of chronic renal failure

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Renal protective effect of enalapril in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2000.062

21 January 2018

Identifiers

10.3317/JRAAS.2000.062

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57703684&oldid=1582905853"